Standards group urges against unique biosimilar names

At a closed door meeting with FDA, the National Council for Prescription Drug Programs (NCPDP) urged the agency to use the same international non-proprietary name (INN) for both biosimilars and their reference biologics. The group -- a not-for-profit that develops national standards on the electronic exchange of healthcare information -- said using unique INNs for "common active ingredients may generally increase confusion, leading to increased safety concerns and possibly medication errors." ...